Cardiac CIP protein regulates dystrophic cardiomyopathy

Xin, He, Jianming, Liu, Fei, Gu, Jinghai, Chen, Yao Wei, Lu, Jian, Ding, Haipeng, Guo, Mao, Nie, Masaharu, Kataoka, Zhiqiang, Lin, Xiaoyun, Hu, Huaqun, Chen, Xinxue, Liao, Yugang, Dong, Wang, Min, Zhong Liang, Deng, William T., Pu, Zhan Peng, Huang, Da Zhi, Wang

Molecular Therapy |

Heart failure is a leading cause of fatality in Duchenne muscular dystrophy (DMD) patients. Previously, we discovered that cardiac and skeletal-muscle-enriched CIP proteins play important roles in cardiac function. Here, we report that CIP, a striated muscle-specific protein, participates in the regulation of dystrophic cardiomyopathy. Using a mouse model of human DMD, we found that deletion of CIP leads to dilated cardiomyopathy and heart failure in young, non-syndromic mdx mice. Conversely, transgenic overexpression of CIP reduces pathological dystrophic cardiomyopathy in old, syndromic mdx mice. Genome-wide transcriptome analyses reveal that molecular pathways involving fibrogenesis and oxidative stress are affected in CIP-mediated dystrophic cardiomyopathy. Mechanistically, we found that CIP interacts with dystrophin and calcineurin (CnA) to suppress the CnA-Nuclear Factor of Activated T cells (NFAT) pathway, which results in decreased expression of Nox4, a key component of the oxidative stress pathway. Overexpression of Nox4 accelerates the development of dystrophic cardiomyopathy in mdx mice. Our study indicates CIP is a modifier of dystrophic cardiomyopathy and a potential therapeutic target for this devastating disease.